ets-1 is a transcription factor known to induce the expression of various genes important for carcinoma progression. However, its clinical significance does not seem to be uniform for all carcinomas. In this study, we investigated the ets-1 expression in 41 extrahepatic bile duct carcinomas (BDC) and 19 cholangiocellular carcinomas (CCC). Epithelial cells of normal ducts only occasionally expressed ets-1, whereas cells of reactive ducts and dysplastic ducts were often positive for this protein. On the other hand, 61.0% of BDC and 21.6% of CCC were classified as ets-1-positive, because more than 5% of the carcinoma cells expressed ets-1. The expression of ets-1 showed inverse relationships with the Ki-67-labeling index and vascular and perineural invasion of BDC, whereas no such relationships could be established in CCC. Furthermore, the well-differentiated BCD more frequently expressed ets-1. These results suggest that ets-1 works as a transcription factor in malignant transformation and progression in early phases of BDC.

Keywords:
ets-1, Bile duct carcinoma, Cholangiocellular carcinoma, Immunohistochemistry, Prognostic factor
1.
Laprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C: A putative second cell-derived oncogene of avian leukemia retrovirus E26. Nature 1983;306:395–397.
2.
Bhat NK, Fisher RJ, Fujiwara S, Ascione R, Papas TS: Temporal and tissue-specific expression of mouse ets genes. Proc Natl Acad Sci USA 1987;84:3161–3165.
3.
Bhat NK, Komschlies KL, Fujiwara S, Fisher RJ, Mathieson BJ, Gregorio TA, Yound HA, Kasik JW, Ozato K, Papas TS: Expression of ets genes in mouse thymocyte subsets and T cells. J Immunol 1989;142:672–675.
4.
Chen JK: The proto-oncogene c-ets 1 is preferentially expressed in lymphoid cells. Mol Cell Biol 1985;5:2993–3000.
5.
Vandenbunder B, Pardanaud L, Jaffredo T, Mirabel MA, Stehelin D: Complementary patterns of expression of c-ets 1, c-myb, and c-myc in the blood-forming system of the chick embryo. Development 1989;107:265–274.
6.
Wernert N, Raes M-B, Lassalle P, Dehouck M-P, Gosselin B, Vandenbunder B, Stehelin D: c-ets 1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992;140:119–127.
7.
Fujiwara S, Fisher RJ, Seth A, Bhat NK, Showalter SD, Zweig M, Papas TS: Characterization and localization of the products of the human homologs of the v-est oncogene. Oncogene 1988;2:99–103.
8.
Koizumi S, Fisher RJ, Fujiwara S, Jorcyk C, Bhat NK, Seth A, Papas TS: Isoforms of the human ets-1 protein: Generation by alternative splicing and differential phosphorylation. Oncogene 1990;5:675–681.
9.
Fisher RJ, Mavrothalassitis G, Kondoh A, Papas TS: High-affinity DNA-protein interactions of the cellular ETS1 protein: The determination of the ETS binding motif. Oncogene 1991;6:2249–2254.
10.
Wasylyk C, Gutman A, Nicholson R, Wasylyk B: c-ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991;10:1127–1134.
11.
Wang CY, Petryniak B, Ho IC, Thompson CB, Leiden JM: Evolutionarily conserved Ets family members display distinct DNA binding specificities. J Exp Med 1992;175:1391–1399.
12.
Kola I, Brooks S, Green AR, Garber R, Tymms M, Papas T: The Ets-1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci USA 1993;90:7588–7592.
13.
Grevin D, Chen JH, Raes MB, Stehelin D, Vandenbunder B, Desbiens X: Involvement of the proto-oncogene c-ets 1 and the urokinase plasminogen activator during mouse implantation and placentation. Int J Dev Biol 1993;37:519–529.
14.
Ito M, Nakayama T, Naito S, Matsuu M, Shichijo K, Sekine I: Expression of Ets-1 transcription factor in relation to angiogenesis in the healing process of gastric ulcer. Biochem Biophys Res Commun 1998;246:123–127.
15.
Liotta LA, Steeg PS, Stetler SWG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327–336.
16.
Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D: The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 1990;346:191–193.
17.
Rosen GD, Barks JL, Iademarco MF, Fisher RJH, Dean DC: An intricate arrangement of binding sites for the Ets family of transcription factors regulates activity of the alpha-4 integrin gene promoter. J Biol Chem 1994;269:15652–15660.
18.
Higashino F, Yoshida K, Noumi T, Seiki M, Fujinaga K: Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 1995;10:1461–1463.
19.
Vandenbunder B, Wernert N, Queva C, Desbiens X, Stehelin D: Does the transcription factor c-ets 1 take part in the regulation of angiogenesis and tumor invasion? Folia Biol (Praha) 1994;40:301–313.
20.
Nerlov C, De Cesare D, Pergola F, Caraccilo A, Blasi F, Johnsen M, Verde P: A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 1992;11:4573–4582.
21.
Japanese Society of Biliary Surgery: General Rules for Surgery and Pathological Studies on Cancer of Biliary Tract, ed 3. 1993.
22.
Hermanek P, Sobin LH (eds): UICC. TNM classification of malignant tumors, ed 4 rev. Berlin, Springer, 1992.
23.
Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, Yamashita S, Sekine I: Expression of the Ets-1 proto-oncogene in human gastric carcinoma. Am J Pathol 1996;149:1931–1939.
24.
Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N, Moro D, Brambilla C, Brambilla E: Expression of c-ets 1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995;147:1298–1310.
25.
Ito T, Nakayama T, Ito M, Naito S, Kanematsu T, Sekine I: Expression of the ets-1 proto-oncogene in human pancreatic carcinoma. Mod Pathol 1998;11:209–215.
26.
Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Sekine I: Expression of the ets-1 proto-oncogene in human thyroid tumors. Mod Pathol 1999;12:61–68.
27.
Charlotte F, L’Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994;144:460–465.
28.
Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A: p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995;22:774–779.
29.
Wernert N, Gilles F, Fafeur V, Bouali F, Raes M-B, Pyke C, Dupressoir T, Seitz G, Vandenbunder B, Stehelin D: Stromal expression of c-Ets 1 transcription factor correlates with tumor invasion. Cancer Res 1994;54:5683–5688.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.